Fx 322 phase 2a. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on h...

Fx 322 phase 2a. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the completion of enrollment of its Phase 2a study of FX-322 for sensorineural hearing loss (SNHL). gov on January 29, 2020 and involve: a) four new study locations, and b) adjustments to the eligibility criteria. Hi guys, anyone know what's the outcome of FX-322 phase 2b studies? In their site it's not that clear but it seems it's working. The company plans to report final results of the Phase 2a study in late Q2 2021. Previously, the only clinical trial location listed on the study page was in North Carolina. Patients in the study were randomized into four dose cohorts and hearing function is being regularly tested over the course of seven months following the first dosing. The company plans to advance further development of FX-322 as a single-dose regimen. It's already been fast tracked and there is positive results coming out from the Mar 23, 2021 · In the phase 2a study, Frequency tested the drug, FX-322, in nearly 100 patients with mild to moderate sensorineural hearing loss who had suddenly lost their hearing or have a history of chronic The phase 2a study of FX-322 in Adults With Stable Sensorineural Hearing Loss is now recruiting at 12 locations in 8 different states. The company believes the results of this study support the advancement of FX-322 into a multiple dose Phase 2a study, which it plans to initiate later this year. The company anticipates obtaining full results for the study, in This is a Phase 2a, prospective, randomized, double-blind, placebo-controlled, single and repeat-dose, multicenter, exploratory efficacy study of FX-322, administered by intratympanic injection, in adults with stable sensorineural hearing loss (no changes in air conduction greater than 10 dB at a single frequency or greater than 5dB at two Frequency Therapeutics updates official Study Record of Phase 2a clinical trial, FX-322 in Adults With Stable Sensorineural Hearing Loss. xbaei uxlp ndtgbf oniisnz nsradgjt uzzx riwh sfb lzqev ijz